Abstract

BackgroundMicroRNAs (miRNAs) can act as oncogenes or tumor suppressors by controlling cell proliferation, differentiation, metastasis and apoptosis, and miRNA dysregulation is involved in the development of pancreatic cancer (PC). Our previous study demonstrated that Gabra3 plays critical roles in cancer progression. However, whether Gabra3 is regulated by miRNAs in PC remains unknown.MethodsThe expression levels of miR-92b-3p and Gabra3 were measured by quantitative PCR (qPCR), immunoblotting, in situ hybridization (ISH) and immunohistochemistry (IHC). The proliferation rate of PC cells was detected by MTS assay. Wound-healing and transwell assays were used to examine the invasive abilities of PC cells. Dual-luciferase reporter assays were used to determine how miR-92b-3p regulates Gabra3. Xenograft mouse models were used to assess the role of miR-92b-3p in PC tumor formation in vivo.ResultsHere, we provide evidence that miR-92b-3p acted as a tumor suppressor in PC by regulating Gabra3 expression. MiR-92b-3p expression levels were lower in PC tissues than corresponding noncancerous pancreatic (CNP) tissues and were associated with a poor prognosis in PC patients. MiR-92b-3p overexpression suppressed the proliferation and invasion of PC cells in both in vivo and in vitro models. Conversely, miR-92b-3p knockdown induced an aggressive phenotype in PC cells. Mechanistically, miR-92b-3p overexpression suppressed Gabra3 expression, which then led to the inactivation of important oncogenic pathways, including the AKT/mTOR and JNK pathways.ConclusionOur results suggest that miR-92b-3p acted as a tumor suppressor by targeting Gabra3-associated oncogenic pathways; these results provide novel insight into future treatments for PC patients.

Highlights

  • MicroRNAs can act as oncogenes or tumor suppressors by controlling cell proliferation, differentiation, metastasis and apoptosis, and miRNA dysregulation is involved in the development of pancreatic cancer (PC)

  • Expressed microRNAs in various kinds of cancer tissues have been revealed by functional studies; many of these miRNAs have been identified as tumor suppressors or onco-miRNAs that modulate tumorigenesis, tumor proliferation, apoptosis, metastasis, and chemo-resistance [5,6,7,8]

  • By using clinical PC tissue samples, we demonstrated an inverse relationship between miR-92b-3p and Gabra3 expression levels; these levels are tightly correlated with PC patient prognosis

Read more

Summary

Introduction

MicroRNAs (miRNAs) can act as oncogenes or tumor suppressors by controlling cell proliferation, differentiation, metastasis and apoptosis, and miRNA dysregulation is involved in the development of pancreatic cancer (PC). Expressed microRNAs (miRNAs) in various kinds of cancer tissues have been revealed by functional studies; many of these miRNAs have been identified as tumor suppressors or onco-miRNAs that modulate tumorigenesis, tumor proliferation, apoptosis, metastasis, and chemo-resistance [5,6,7,8]. MiRNAs can influence cancer proliferation and metastasis through multiple pathways, such as the AKT/mTOR. Several miRNA-based therapeutics have entered clinical trials; one such example is a mimic of the tumor suppressor miR-34, which has reached phase I clinical trials for the treatment of cancer [17]. Investigations of the complex miRNA-associated pathways may offer insight into identifying new therapeutic targets for treating PC patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call